Safety and clinical efficacy of immune checkpoint inhibitors in pediatric hepatocellular carcinoma: a case report and review of the literature
The efficacy and safety of ICIs in pediatric HCC require further validation. Ongoing prospective studies will determine their clinical role, necessitating cautious application until robust evidence emerges.
Authors
- Xuejiao Wen (ORCID: https://orcid.org/0000-0003-3695-7210)
- Jianming Ye (ORCID: https://orcid.org/0000-0003-3215-7726)
- Jing Wang (ORCID: https://orcid.org/0000-0001-9981-5530)
- Jun Chi
- Li Huang (ORCID: https://orcid.org/0000-0003-4249-059X)
- Xinping Wang (ORCID: https://orcid.org/0000-0002-0272-8156)
- Xiaoli Zeng (ORCID: https://orcid.org/0000-0001-6974-0400)
- Xiaoting Zhong
Institutions
- Jiangxi Provincial Cancer Hospital (CN)
- Gannan Medical University (CN)
- First Affiliated Hospital of Gannan Medical University (CN)
- Jiangxi College of Applied Technology (CN)
- Jiangxi University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-08-15
- DOI
- https://doi.org/10.3389/fonc.2025.1576892
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00